April 17 (Reuters) - U.S. Food and Drug Administration:
* U.S. FDA SAYS APPROVED CRYSVITA (BUROSUMAB) TO TREAT ADULTS & CHILDREN AGES 1 YEAR & OLDER WITH X-LINKED HYPOPHOSPHATEMIA, AN INHERITED FORM OF RICKETS
* U.S. FDA SAYS GRANTED APPROVAL OF CRYSVITA TO ULTRAGENYX PHARMACEUTICAL INC Source text for Eikon: Further company coverage:
